• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Crinone 8%
    / Merck

    Active Ingredient
    Progesterone 8% w/w

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    15 X 1.45 g

    partial basket chart 58548 3745


    Posology: Intravaginal application.
    Treatment of infertility due to inadequate luteal phase: One application (1.125g 8% gel) every day, starting after documented ovulation or arbitrarily on the 18th-21st day of the cycle.
    Use during in-vitro fertilisation: Daily application of Crinone 8% gel should be continued for 30 days if there is laboratory evidence of pregnancy.
    Paediatric population: Not applicable.
    Older people: Not applicable.
    Method of Administration: Crinone is applied directly from the specially designed sealed applicator into the vagina. The applicator should be removed
    from the sealed wrapper. The twist-off cap should not be removed at this time.


    Treatment of infertility due to inadequate luteal phase. For use during in-vitro fertilization, where infertility is mainly due to tubal, idiopathic or endometriosis linked sterility associated with normal ovulatory cycles.


    Known sensitivity, undiagnosed vaginal bleeding, liver dysfunction or disease, known or suspected malignancy of the breast or genital organs, missed abortion. Active thrombophlebitis or thromboembolic disorders, or a history of hormone-associated thrombophlebitis or thromboembolic disorders.

    Special Precautions

    The pretreatment physical examination should include special reference to breast and pelvic organs, as well as Papanicolaou smear. In cases of breakthrough bleeding, as in all cases of irregular vaginal bleeding, nonfunctional causes should be considered. In cases of undiagnosed vaginal bleeding, adequate diagnostic measures should be undertaken. Because progestogens may cause some degree of fluid retention, conditions which might be influenced by this factor (e.g. epilepsy, migraine, asthma, cardiac or renal dysfunction) require careful observation. The pathologist should be advised of progesterone therapy when relevant specimens are submitted. Patients who have a history of psychic depression should be carefully observed. Diabetic patients should be carefully observed while receiving progestin therapy.

    Side Effects

    Abdominal pain, perineal pain, headache, constipation, diarrhea, nausea, vomiting. Arthralgia, depression, decreased libido, nervousness, somnolence, dyspareunia, nocturia.
    See prescribing information for full details.

    Drug interactions

    See prescribing information for full details.

    Merck Serono S.A., Switzerland
    Licence holder